The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma. Sep 2011 - Curr. Top. Microbiol. Immunol.; 351:0070-217X [PMID:21681685] [Oosterhoff D] [Sluijter BJ] [Hangalapura BN] [de Gruijl TD]
Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Sep 2011 - Clin. Cancer Res.; 17(17):1078-0432 [PMID:21771874] [Lesterhuis WJ] [de Vries IJ] [Schreibelt G] [Lambeck AJ] [Aarntzen EH] [Jacobs JF] [Scharenborg NM] [van de Rakt MW] [de Boer AJ] [Croockewit S] [van Rossum MM] [Mus R] [Oyen WJ] [Boerman OC] [Lucas S] [Adema GJ] [Punt CJ] [Figdor CG]
Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. Feb 2011 - :1476-5462 [PMID:21307889] [Steele JC] [Rao A] [Marsden JR] [Armstrong CJ] [Berhane S] [Billingham LJ] [Graham N] [Roberts C] [Ryan G] [Uppal H] [Walker C] [Young LS] [Steven NM]
Changes in peripheral blood level of regulatory T cells in malignant melanoma patients during treatment with dendritic cell vaccination and low dose IL-2. Jan 2011 - :1365-3083 [PMID:21204893] [Bjoern J] [Brimnes MK] [Andersen MH] [Thor Straten P] [Svane IM]
New approaches to the development of adenoviral dendritic cell vaccines in melanoma. Dec 2010 - Curr Opin Investig Drugs; 11(12):2040-3429 [PMID:21154122] [Butterfield LH] [Vujanovic L]
Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Nov 2010 - Cancer Immunol. Immunother.:1432-0851 [PMID:21069321] [Lesterhuis WJ] [Schreibelt G] [Scharenborg NM] [Brouwer HM] [Gerritsen MJ] [Croockewit S] [Coulie PG] [Torensma R] [Adema GJ] [Figdor CG] [de Vries IJ] [Punt CJ]
Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival. Oct 2010 - :1432-0851 [PMID:20960187] [Cornforth AN] [Fowler AW] [Carbonell DJ] [Dillman RO]
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment, a phase I/II study in metastatic melanoma patients. Aug 2010 - :1078-0432 [PMID:20736326] [Jacobs JF] [Punt CJ] [Lesterhuis WJ] [Sutmuller RP] [Brouwer HM] [Scharenborg NM] [Klasen IS] [Hilbrands LB] [Figdor CG] [de Vries IJ] [Adema GJ]
Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Apr 2010 - :1477-2566 [PMID:20429791] [Trepiakas R] [Berntsen A] [Hadrup SR] [Bjørn J] [Geertsen PF] [Straten PT] [Andersen MH] [Pedersen AE] [Soleimani A] [Lorentzen T] [Johansen JS] [Svane IM]
The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin. Patients with advanced melanoma usually do not benefit from conventional chemotherapy treatment. There is therefore a true need for a new kind of therapy for melanoma. One factor responsible for the poor prognosis of melanoma is the inhibitor of apoptosis protein (IAP) family member Livin. In this Dec 2009 - J. Virol.; 84(1):1098-5514 [PMID:19864394] [Lazar I] [Yaacov B] [Shiloach T] [Eliahoo E] [Kadouri L] [Lotem M] [Perlman R] [Zakay-Rones Z] [Panet A] [Ben-Yehuda D]
Mechanisms of murine dendritic cell antitumor dysfunction in aging. Oct 2009 - Cancer Immunol. Immunother.; 58(12):1432-0851 [PMID:19082999] [Grolleau-Julius A] [Abernathy L] [Harning E] [Yung RL]
Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy. Aug 2009 - J. Clin. Immunol.; 29(5):1573-2592 [PMID:19421847] [Cornforth AN] [Lee GJ] [Fowler AW] [Carbonell DJ] [Dillman RO]
Genetically engineered Newcastle disease virus for malignant melanoma therapy. Jun 2009 - Gene Ther.; 16(6):1476-5462 [PMID:19242529] [Zamarin D] [Vigil A] [Kelly K] [García-Sastre A] [Fong Y]
Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. May 2009 - Prostate; 69(9):1097-0045 [PMID:19267351] [Kim S] [Lee JB] [Lee GK] [Chang J]
Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. May 2009 - Clin. Cancer Res.; 15(10):1078-0432 [PMID:19417017] [Bonehill A] [Van Nuffel AM] [Corthals J] [Tuyaerts S] [Heirman C] [François V] [Colau D] [van der Bruggen P] [Neyns B] [Thielemans K]
